Therapeutic Effects of Qifangfeixian Granules on Pulmonary Fibrosis in Patients with Interstitial Lung Disease

Abstract

Objective

To investigate the curative effect of the Qifangfeixian granule on interstitial lung disease (ILD).

Methods

This study combined animal experiments and clinical trials. Pathological changes in bleomycin (BLM)-induced pulmonary fibrosis in mice were assessed using hematoxylin and eosin (H&E), Masson, and Sirius Red staining. In the clinical study, 40 ILD patients were enrolled, with 20 in the control group and 20 in the treatment group. The treatment group received Qifangfeixian granules in addition to standard therapy for 12 weeks. Pulmonary function parameters, including forced vital capacity (FVC, L), FVC_pred%, diffusing capacity for carbon monoxide (DLCO, mmol/min/kPa), and DLCO_pred%, were measured before and after treatment.

Results

Compared with those of the control group, the inflammatory infiltration and collagen fibres in the BLM group were significantly increased, and the inflammatory infiltration and collagen fibres in the BLM group were significantly reduced after Qifangfeixian granule treatment. Compared with those in the control group, the lung function parameters in the treatment group were significantly improved. Specifically, the FVC increased by +0.10 ± 0.18 L in the treatment group, whereas the control group showed a decrease of –0.05 ± 0.21 L (P = 0.008). Additionally, FVC_pred% was improved significantly in the treatment group (+2.6% ± 5.3%) compared with the control group (–2.0% ± 6.7%, P = 0.009).

Conclusion

Qifangfeixian granules can improve not only the pulmonary fibrosis of BLM-induced model mice but also the pulmonary function of patients with ILD in practice, and their clinical efficacy is accurate.

Keywords

Qifangfeixian granule / Traditional Chinese Medicine / Bleomycin / Interstitial lung diseases / Pulmonary fibrosis / Transforming growth factor beta / Smad proteins / Pulmonary function test

References

[1] Guler SA, Corte TJ. Interstitial Lung Disease in 2020: A History of Progress. Clin Chest Med., 2021, 42(2): 229-239

[2] Wijsenbeek M, Cottin V. Spectrum of Fibrotic Lung Diseases. N Engl J Med., 2020, 383(10): 958-968

[3] Yang DR, Ren T. Overview of interstitial lung disease. J Clin Med (Chinese). 202,39(10):649–652.

[4] Raghu G, Selman M. Nintedanib and pirfenidone New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions. Am J Respir Crit Care Med., 2015, 191(3): 252-254

[5] Jiang HY, Yang H, Dai Q, et al.. Clinical effect of Buyang Huanwu Decoction on pulmonary fibrosis associated with connective tissue disease of qi deficiency and blood stasis syndrome. Chin J Exp Formulae (Chinese)., 2022, 28(21): 104-112

[6] Wei Y, Guo SJ, Song YL, et al.. Recognition of the syndrome of lung flacuity, lung bi and pulmonary interstitial fibrosis. Jilin Chin Med (Chinese)., 2020, 40(01): 28-32

[7] Ding DL, Shen XB, Yao JH, et al. Research progress of traditional Chinese medicine in the treatment of pulmonary fibrosis. Chin Herbal Med (Chinese). 201;52(22):7006–7024.

[8] Yu N, Zhou JW, Li X, et al.. Interpretation of the adult idiopathic pulmonary fibrosis (updated) and progressive pulmonary fibrosis clinical practice guidelines (2022 edition). Chin J Modern Med (Chinese)., 2019, 33(14): 1-8

[9] Zou QH, Lu YW, Zhou JG, et al.. Diagnosis and treatment of interstitial lung disease associated with connective tissue disease. Chin J Intern Med (Chinese)., 2002, 61(11): 1217-1223

[10] Jenkins RG, Moore BB, Chambers RC, et al.. An Official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis. Am J Respir Cell Mol Biol., 2017, 56(5): 667-679

[11] Szapiel SV, Elson NA, Fulmer JD, et al.. Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse. Am Rev Respir Dis., 1979, 120(4): 893-899

[12] Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol., 1988, 41(4): 467-470

[13] Chen X, Li YZ, Fu YJ, et al.. Disease burden of interstitial lung disease and pulmonary sarcoidosis in China, 1990–2019. Dis Surveil (Chinese)., 2018, 38(04): 473-480

[14] He YK, Yang GH, Zheng YQ, et al.. Etiology and pathogenesis of lung interstitial disease associated with connective tissue disease. Sichuan J Tradit Chin Med (Chinese)., 2015, 33(04): 32-34

[15] Tao WL. Overview of TCM treatment of interstitial pneumonia. Henan Chin Med (Chinese)., 2014, 34(07): 1421-1423

[16] Sun LY, Yuan WT, Shi XH. Research progress of clinical application and mechanism of action of Fangji Huangqi Decoction. Inform Chin Med (Chinese)., 2023, 40(04): 90-95

[17] Zhang DD, Li R, Liu XM. Research progress of the mechanism of Astragalus in the intervention of pulmonary fibrosis. Chin Med Rev (Chinese), 2021, 27(07): 143-147

[18] Li H, Li GQ, Liu JL, et al.. Clinical Observation on the Treatment of Pulmonary Interstitial Fibrosis with Qi-Strengthening, Blood-Activating and Meridian-Relaxing Decoction. Chin J Inf Tradit Chin Med (Chinese)., 2009, 16(2): 65-66

[19] Zhu X. Modern Pharmacological Research on Astragalus and Its New Clinical Applications. Chin Med Mod Dist Edu Chin (Chinese)., 2010, 8(15): 72

[20] Yang CG, Mao XL, Wu JF, et al.. Amelioration of Lung Fibrosis by Total Flavonoids of Astragalus via Inflammatory Modulation and Epithelium Regeneration. Am J Chin Med., 2023, 51(2373-389

[21] He LH, Luan HJ, He J, et al.. Research progress of Fangji Huangqi Decoction in the treatment of rheumatoid arthritis. Jiangxi Chin Med (Chinese)., 2023, 54(03): 70-72

[22] Qin J, Zhao MS, Li J. The Effect of Danshen Saponin Intervention on the TGF-β1/Smads Signaling Pathway in Rat Pulmonary Fibrosis. Chin J Pathophysiol (Chinese)., 2013, 29(5): 937-940 946

Funding

National Natural Science Foundation of China(82170081)

Tongji Hospital(No.2024TJCR005)

RIGHTS & PERMISSIONS

The Author(s), under exclusive licence to the Huazhong University of Science and Technology